Trial Profile

A phase 1 study of IMC T119C in solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMC T119C (Primary)
Indications Solid tumours
Focus Adverse reactions
Acronyms PRAME-A24

Most Recent Events

08 May 2024 According to an Immunocore media release, company is on track for Investigational New Drug (IND) or Clinical Trial Application (CTA) submissions for IMC-T119C in the fourth quarter of 2024.
17 Aug 2023 New trial record
10 Aug 2023 According to an Immunocore media release, company is on-track for IND/CTA submission in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com